Posted inBiotechnology
Pfizer’s mRNA flu vaccine shows 34.5% greater efficacy than standard shot in phase 3
Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential…
Posted inMedical Technology
Abbott dives into cancer diagnostics with $23B buyout of Exact Sciences
In January, Exact Sciences CEO Kevin Conroy told us that 2025 was shaping up to be a transformative year for…
Posted inBiotechnology
Ensoma halves workforce after transitioning genetic medicine to the clinic
Genetic medicine outfit Ensoma is halving its workforce, with most of the impacted roles related to platform research functions. The…
Posted inBiotechnology
Applied Tx lays off 46% of workforce as rare disease drug approval looks out of reach
Facing skepticism from analysts about whether it has the resources to take its rare disease drug to market, Applied Therapeutics…
Posted inBiotechnology
Novartis CEO paid top dollar for Avidity to become a ‘leader in neuromuscular diseases’
Novartis may have signed off on the second-largest pharma acquisition of 2025 so far, but, as the company’s CEO sees…
Posted inBiotechnology
Aspen enriches Parkinson’s cell therapy trial with Kite-backed $115M series C
Aspen Neuroscience’s cash reserves have been fertilized with a $115 million series C fundraise that will enrich the biotech’s ongoing…
Posted inBiotechnology
GSK picks Flagship’s Quotient, ProFound as 1st biotech partners for $7B pact
GSK has picked a novel protein biotech and a genomics biotech as its first collaborators under a $7 billion biobucks…
Posted inBiotechnology
Merck KGaA links up with Flagship’s Valo Health in search for Parkinson’s targets, offers $3B in biobucks
Merck KGaA has become the latest Big Pharma to tap the drug discovery expertise of Flagship Pioneering’s Valo Health. The…
Posted inBiotechnology
ExamOne executive details how mobile phlebotomy is reshaping clinical research
Mobile phlebotomy is playing a growing role in clinical research as trial sponsors turn to at-home services to improve access…
Posted inBiotechnology
Tempest turns to Factor for lifeline, trading majority stake for CAR-Ts and CEO
After laying off 80% of staffers this spring, Tempest Therapeutics is acquiring several CAR-T programs from Factor Bioscience and bringing…